Donanemab (brand name Kisunla) is an intravenous monoclonal antibody approved in the United States for treatment of early symptomatic Alzheimer's disease in adults with confirmed amyloid-beta pathology[1][2]. It is an IgG1 antibody that preferentially binds pyroglutamate-modified amyloid-beta (N3pG-Aβ), an epitope enriched in deposited plaques rather than soluble monomeric peptide[3].
Clinically, donanemab belongs to the same disease-modifying anti-amyloid class as Lecanemab (Leqembi), but differs in epitope preference, treatment-stopping rules based on plaque clearance, and trial stratification by baseline tau burden[2:1][4].
Donanemab's key mechanism differs from other anti-amyloid antibodies:
| Antibody | Target Epitope | Preferred Form |
|---|---|---|
| Donanemab | N3pG-Aβ (pyroglutamate) | Deposited plaques |
| Lecanemab | Aβ protofibrils | Soluble aggregates |
| Aducanumab | Multiple Aβ forms | Plaques and monomers |
The Phase 2 TRAILBLAZER-ALZ trial enrolled 272 patients with early AD[4:1]:
This trial pioneered the approach of stopping treatment once amyloid plaques are cleared, potentially reducing treatment burden and ARIA risk.
The Phase 3 TRAILBLAZER-ALZ 2 trial enrolled 1,736 patients with early AD[2:2]:
| Tau Level | CDR-SB Benefit | Clinical Meaning |
|---|---|---|
| Low/Medium | Greater benefit | Earlier intervention more effective |
| High | Moderate benefit | Advanced disease less responsive |
The results support earlier intervention in the disease process when there is less established tau pathology.
| Biomarker | Change |
|---|---|
| Brain amyloid (Centiloid) | Significant reduction |
| CSF p-tau181 | Reduced |
| Tau PET | Slower accumulation in low-tau group |
| ARIA Type | Donanemab | Placebo |
|---|---|---|
| ARIA-E (edema) | ~24% | ~2% |
| ARIA-H (hemorrhage) | ~7% | ~2% |
Monitoring Protocol:
Donanemab represents a paradigm shift with limited-duration treatment:
This approach may:
Early Alzheimer's Disease (MCI due to AD or mild dementia) with confirmed amyloid pathology.
| Feature | Donanemab | Lecanemab | Aducanumab |
|---|---|---|---|
| Target | N3pG-Aβ plaques | Protofibrils | Mixed |
| Dosing | 350 mg q4w | 10 mg/kg q2w | 10 mg/kg q4w |
| Treatment approach | Limited duration | Continuous | Continuous |
| ARIA-E rate | ~24% | ~13% | ~35% |
| CDR-SB benefit | ~0.70 | ~0.45 | ~0.39 |
The study of Donanemab (Kisunla) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
FDA. (2024). Donanemab (Kisunla) Prescribing Information. https://www.fda.gov ↩︎
Sims, J.R., et al. (2023). Donanemab in Early Alzheimer's Disease. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2303370 ↩︎ ↩︎ ↩︎
Ovod, V., et al. (2017). Amyloidloidogen. Nature Neuroscience. https://doi.org/10.1038/nn.4587 ↩︎
Mintun, M.A., et al. (2021). Donanemab in Early Alzheimer's Disease. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2100708 ↩︎ ↩︎